New injection shows promise for nerve disease safety
NCT ID NCT05361031
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times
Trial info
This early-phase trial tested whether an experimental drug called Engensis (VM202) is safe when injected into the weakened leg muscles of people with Charcot-Marie-Tooth disease type 1A (CMT1A). Twelve adults with mild to moderate CMT1A received multiple injections over 270 days. Researchers monitored side effects and measured changes in nerve function to see if the treatment might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Samsung Medical Center, Seoul National University Hospital
Seoul, 06351, South Korea
Conditions
Explore the condition pages connected to this study.